Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodi...

Descripción completa

Detalles Bibliográficos
Autores principales: Page, David B., Bear, Harry, Prabhakaran, Sangeetha, Gatti-Mays, Margaret E., Thomas, Alexandra, Cobain, Erin, McArthur, Heather, Balko, Justin M., Gameiro, Sofia R., Nanda, Rita, Gulley, James L., Kalinsky, Kevin, White, Julia, Litton, Jennifer, Chmura, Steven J., Polley, Mei-Yin, Vincent, Benjamin, Cescon, David W., Disis, Mary L., Sparano, Joseph A., Mittendorf, Elizabeth A., Adams, Sylvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783471/
https://www.ncbi.nlm.nih.gov/pubmed/31602395
http://dx.doi.org/10.1038/s41523-019-0130-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783471/
https://www.ncbi.nlm.nih.gov/pubmed/31602395
http://dx.doi.org/10.1038/s41523-019-0130-x

Ejemplares similares